# OnCo record ntrk (target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/targets/ntrk/>
  a schema:BioChemEntity ;
  onco:kind "target" ;
  schema:identifier "ntrk" ;
  schema:name "NTRK"@en ;
  schema:description "Rare gene fusions found across dozens of cancer types; the first target where a drug was approved for any tumour carrying it."@en ;
  schema:url <https://onco.cc/targets/ntrk/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Trk_receptor> ;
  owl:sameAs <http://www.wikidata.org/entity/Q24719927> ;
  schema:citation <https://en.wikipedia.org/wiki/Trk_receptor> ;
  onco:tag "driver", "tumour-agnostic" ;
  schema:alternateName "NTRK1/2/3" ;
  onco:targetClass "kinase" ;
  onco:related <https://onco.cc/biomarkers/ntrk-fusion/> ;
  onco:cancers <https://onco.cc/cancers/sarcoma/>, <https://onco.cc/cancers/thyroid/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/gallbladder/>, <https://onco.cc/cancers/nsclc/> ;
  onco:drugs <https://onco.cc/drugs/trk-950/> ;
  onco:companies <https://onco.cc/companies/lucence/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/thyroid-cancer-signalling/> ;
  onco:terms <https://onco.cc/terms/gene-fusion/>, <https://onco.cc/terms/tumour-agnostic/> ;
  onco:trials <https://onco.cc/trials/nct06010342/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-philip-kras-wild-type-pancreatic-ccr-2022/>, <https://onco.cc/key-papers/paper-oreilly-hechtman-ntrk-fusion-pancreatic-larotrectinib-ann-oncol-2019/>, <https://onco.cc/key-papers/paper-giraldo-gallbladder-msk-impact-ccr-2022/>, <https://onco.cc/key-papers/paper-cowzer-biliary-targeted-therapy-determinants-ccr-2026/> .